Qingfeng Pharma Group

English

中文

Home

Providing sustainable and high-quality service for human health

Become a leading provider of medical health products and service

Innovating, Efficiency, Striving, Sharing

12/20

2024

Qingfeng will attend the 2025 J.P. Morgan Healthcare Conference

Qingfeng Pharmaceutical Group will attend “The 43rd Annual J.P. Morgan Healthcare Conference” in San Francisco, from January 13-16, 2025. Qingfeng would like to hold one-on-one meetings ...

07/08

2024

Qingfeng Pharmaceutical's Eribulin Mesilate Injection Approved for Marketing in the U.S.

On June 28, the Eribulin Mesilate Injection developed by Qingfeng Pharmaceutical Group was approved for marketing by the U.S. Food and Drug Administration (FDA), making Qingfeng Pharmaceutical the ...

07/06

2024

First in China! Qingfeng Pharmaceutical's Brivaracetam Tablets Approved for Marketing

On June 28, the Brivaracetam tablets (trade name: Qingruitan®) developed by Qingfeng Pharmaceutical Group were officially approved for marketing by the National Medical Products Administration. The...